Related Experiment Videos
Clinical trials: types, design, and end-points
1University of Medicine and Dentistry of New Jersey-Scleroderma Program, New Brunswick, New Jersey 08903-0019, USA. seiboljr@umdnj.edu
Abstract:
Although the pathogenesis of systemic sclerosis is poorly understood, an increasing number of high quality clinical research trials are attempting to modify the overall disease outcome. Survival has improved, largely through therapies focused on single organs. Candidate outcome measures have been tested and a consensus template for trial design has evolved. The complexity of process in systemic sclerosis renders unlikely that an agent of focused mechanism of therapeutic effect will alter all cardinal features of illness.
Insights
Systemic sclerosis research is advancing with new clinical trials and improved survival rates. However, the complex nature of this disease means single-target therapies may not address all its features.
Area of Science:
- Rheumatology
- Immunology
- Clinical Research
Background:
- Systemic sclerosis pathogenesis remains poorly understood.
- Clinical research trials are increasingly focused on modifying disease outcomes.
- Survival rates have improved, primarily due to organ-specific therapies.
Purpose of the Study:
- To review the evolution of clinical trial design in systemic sclerosis.
- To assess the impact of current therapeutic strategies.
- To discuss the challenges in developing comprehensive treatment approaches.
Main Methods:
- Review of high-quality clinical research trials in systemic sclerosis.
- Analysis of candidate outcome measures and trial design templates.
- Evaluation of therapeutic strategies targeting single organs.
Main Results:
- Survival in systemic sclerosis has improved through organ-focused therapies.
- Candidate outcome measures have been evaluated.
- A consensus template for trial design has emerged.
Conclusions:
- The complexity of systemic sclerosis suggests that single-mechanism therapies are unlikely to resolve all disease manifestations.
- Future research may require broader therapeutic strategies.
- Continued development in clinical trial design is essential for systemic sclerosis research.